anti-doping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-12 and is reviewed periodically as new material appears.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
By 1954, the United States was producing 910 t (2 million lb) of antibiotics each year, of which 220 t (490,000 lb) was going into animal feed; in the 1990s, the United States was producing 23,000 t (50 million lb) of antibiotics per year, of which half was going to livestock. The largest user remained the poultry industry, which consumed 4,800 t (10.5 million lb) of antibiotics each year, compared to 4,700 t (10.3 million lb) for hogs and 1,700 t (3.7 million lb) for cattle. A 1981 study by the Council for Agricultural Science and Technology estimated that banning their use in animal feed could cost American consumers up to $3.5 billion a year (equivalent to $12.39 billion in 2025) in increased food prices. The story was similar in the UK, where 44 per cent of antibiotic production was consumed by animals by 1963. By the mid-1950s, there were reports in the United States that milk was not curdling to make cheese. The FDA found that the milk was contaminated with penicillin, which was killing the bacteria required for cheesemaking. In 1963, the WHO reported high levels of penicillin in milk worldwide. People who were allergic to penicillin could now get a reaction from drinking milk. A committee chaired by Lord Netherthorpe was established in the UK in 1960 to inquire into the use of antibiotics in animal feed. In 1962, the committee recommended that restrictions on the use of antibiotics in animals be relaxed.
=== Early years === Established in 1903 in Singapore, Cold Storage started as a small depot storing and selling mainly frozen meat. Cold Storage was then known as the Singapore Cold Storage Company, and was the main manufacturer of ice in Singapore. Taking advantage of the booming ice manufacturing and refrigeration business, Cold Storage ventured into the ice cream business. In 1923, a small factory was set up at the Borneo Wharf of the Harbourfront district to manufacture ice cream under the Paradise brand. In its early days, the company's primary concern was to have a quick and profitable turnover of its imported meats and range of products. Cold Storage later shifted from counter-service to self-service, introducing the supermarket to Singapore.
Bidentate ligands bind to metal ions forming a chelate ring. Ligands of higher denticity form two or more chelate rings. Ethylenediamine, 2,2'-bipyridine, and 1,10-phenanthroline form C2N2M chelate rings. Just like in organic chemistry, 5- and 6-membered chelate rings predominate.
== ANA subtypes == ANAs are found in many disorders, as well as some healthy individuals. These disorders include: systemic lupus erythematosus (SLE), rheumatoid arthritis, Sjögren syndrome, scleroderma, polymyositis, dermatomyositis, primary biliary cirrhosis, drug induced lupus, autoimmune hepatitis, multiple sclerosis, discoid lupus, thyroid disease, antiphospholipid syndrome, juvenile idiopathic arthritis, psoriatic arthritis, juvenile dermatomyositis, idiopathic thrombocytopaenic purpura, infection and cancer. These antibodies can be subdivided according to their specificity, and each subset has different propensities for specific disorders.
Sources: en.wikipedia.org
After the First World War, he went on to teach physiology at the University of Toronto, where he became director of the physiology lab and an assistant to the dean of the medical faculty, Thorburn Brailsford Robertson. He researched various topics in physiology and biochemistry, among which were the chemism of Mycobacterium tuberculosis, electroshocks, creatinine metabolism and blood circulation in the brain. In 1905 he became interested in carbohydrate metabolism and diabetes, publishing a series of scientific papers and several monographs on the subject from then on. Additionally, Macleod was a popular lecturer and an influential contributor to the development of the six-year course in medicine at the University of Toronto.
But it did get a little close there for a while. As you may know, there were 61 planes in the air headed toward Haïti at the time they finally agreed. And at one point General Biamby came in and told General Cédras that he had just gotten word on his telephone that the airplanes had taken off from Pope Air Force Base, with soldiers from Fort Bragg, and that both disconcerted them and caused them to be suspicious of the intent of the negotiations, but it also created a situation where immediately after that, the key points they had been refusing to agree to were agreed to, a date certain, other matters that I won't go into in detail here.
At the beginning of Hong Kong's opening up, Western medicine was not yet popular, and Western medicine doctors were mostly foreigners; local residents mostly relied on Chinese medicine practitioners. In 1841, the British government of Hong Kong issued an announcement pledging to govern Hong Kong residents in accordance with all the original rituals, customs and private legal property rights. As traditional Chinese medicine had always been used in China, the use of traditional Chinese medicine was not regulated. The establishment in 1870 of the Tung Wah Hospital was the first use of Chinese medicine for the treatment in Chinese hospitals providing free medical services. As the promotion of Western medicine by the British government started from 1940, Western medicine started being popular among Hong Kong population. In 1959, Hong Kong had researched the use of traditional Chinese medicine to replace Western medicine.
Alexios' concentration of power in the hands of his Komnenos dynasty meant the most serious political threats came from within the imperial family—before his coronation, John II had to overcome his mother Irene and his sister Anna, and the primary threat during his reign was his brother Isaac. John campaigned annually and extensively—he fought the Pechenegs in 1122, the Hungarians in the late 1120s, and the Seljuks throughout his reign, waging large campaigns in Syria in his final years—but he did not achieve large territorial gains. In 1138, John raised the imperial standard over the Crusader Principality of Antioch to intimidate the city into allying with the Byzantines, but did not attack, fearing that it would provoke western Christendom to respond. Manuel I used the considerable financial resources left by his father in pursuit of his ambitions, and also to secure the empire's position in an increasingly multilateral geopolitical landscape. Through a combination of diplomacy and subsidies, he cultivated a network of allies and client rulers around the empire: the Turks of the Sultanate of Rum, the Kingdom of Hungary, the Cilician Armenians, Balkan princes, Italian and Dalmatian cities, and most importantly Antioch and the Crusader States, marrying one of their princesses in 1161. Manuel managed the difficult passage of the Second Crusade through Byzantine territories in 1147, but the campaign's failure was blamed on the Byzantines by western contemporaries.
from quantiles of FT4 and TSH concentration (as determined based on cumulative distribution functions). Per definition the TFQI has a mean of 0 and a standard deviation of 0.37 in a reference population. Higher values of TFQI are associated with obesity, metabolic syndrome, impaired renal function, diabetes, and diabetes-related mortality. TFQI results are also elevated in takotsubo syndrome, potentially reflecting type 2 allostatic load in the situation of psychosocial stress. Reductions have been observed in subjects with schizophrenia after initiation of therapy with oxcarbazepine, potentially reflecting declining allostatic load.
Sources: en.wikipedia.org
== Mechanism of action == "Cromolyn works because it prevents the release of mediators that would normally attract inflammatory cells and because it stabilizes the inflammatory cells. MCT mast cells found in the mucosa are stabilised." Nedocromil is another mast cell stabilizer that also works in controlling asthma. The underlying mechanism of action is not fully understood; for while cromoglicate stabilizes mast cells, this mechanism is probably not why it works in asthma. Pharmaceutical companies have produced 20 related compounds that are equally or more potent at stabilising mast cells and none of them have shown any anti-asthmatic effect. It is more likely that these work by inhibiting the response of sensory C fibers to the irritant capsaicin, inhibiting local axon reflexes involved in asthma, and may inhibit the release of preformed T cell cytokines and mediators involved in asthma. It is known to somewhat inhibit chloride channels (37% ± 7%) and thus may inhibit the:
=== Patentability issues === As indicated above, some mammals typically used for food production (such as goats, sheep, pigs, and cows) have been modified to produce non-food products, a practice sometimes called pharming. Use of genetically modified goats has been approved by the FDA and EMA to produce ATryn, i.e. recombinant antithrombin, an anticoagulant protein drug. These products "produced by turning animals into drug-manufacturing 'machines' by genetically modifying them" are sometimes termed biopharmaceuticals. The patentability of such biopharmaceuticals and their process of manufacture is uncertain. Probably, the biopharmaceuticals themselves so made are unpatentable, assuming that they are chemically identical to the preexisting drugs that they imitate. Several 19th-century United States Supreme Court decisions hold that a previously known natural product manufactured by artificial means cannot be patented. An argument can be made for the patentability of the process for manufacturing a biopharmaceutical, however, because genetically modifying animals so that they will produce the drug is dissimilar to previous methods of manufacture; moreover, one Supreme Court decision seems to hold open that possibility. On the other hand, it has been suggested that the recent Supreme Court decision in Mayo v.
Germany is a federal, parliamentary, representative democratic republic. Federal legislative power is vested in the parliament consisting of the Bundestag (Federal Diet) and Bundesrat (Federal Council), which together form the legislative body. The Bundestag is elected through direct elections using a personalised proportional representation system with a 5% (or 3 seats) threshold. The members of the Bundesrat represent and are appointed by the governments of the sixteen federated states. The German political system operates under a framework laid out in the 1949 constitution known as the Grundgesetz (Basic Law). Amendments generally require a two-thirds majority of both the Bundestag and the Bundesrat; the fundamental principles of the constitution, as expressed in the articles guaranteeing human dignity, the separation of powers, the federal structure, and the rule of law, are valid in perpetuity. The president, who has been Frank-Walter Steinmeier since 2017, is the head of state and invested primarily with representative responsibilities and powers. He is elected by the Bundesversammlung (federal convention), an institution consisting of the members of the Bundestag and an equal number of state delegates. The second-highest official in the German order of precedence is the Bundestagspräsident (president of the Bundestag), who is elected by the Bundestag and responsible for overseeing the daily sessions of the body.
== Chemistry == Flucloxacillin is insensitive to beta-lactamase (also known as penicillinase) enzymes secreted by many penicillin-resistant bacteria. The presence of the isoxazolyl group on the side chain of the penicillin nucleus facilitates the β-lactamase resistance, since they are relatively intolerant of side chain steric hindrance. Thus, it is able to bind to penicillin-binding proteins and inhibit peptidoglycan crosslinking, but is not bound by or inactivated by β-lactamases.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.